DOCSLIB.ORG

2004400 October 2004, Change Report and NCD Coding Policy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report April 2012 Clinical Diagnostic Laboratory Services Health & Human Services Department Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 CMS Email Point of Contact: [email protected] TDD 410.786.0727 Fu Associates, Ltd. Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. NCD Manual Changes Date Reason Release Change Edit The following section represents NCD Manual updates for April 2012. *04/01/12 *ICD-9-cm code range *2012200 *376.21-376.22 *(190.15) Blood Counts and descriptors Endocrine exophthalmos revised 376.21-376.9 Disorders of the orbit, *376.40-376.47 except 376.3 Other Deformity of orbit exophthalmic conditions (underlining *376.50-376.52 in original) Enophthalmos *376.6 Retained (old) foreign body following penetrating wound of orbit *376.81-376.82 Orbital cysts; myopathy of extraocular muscles *376.89 Other orbital disorders *376.9 Unspecified disorder of orbit The following section represents NCD Manual updates for January 2012. 01/01/12 Per CR 7621 add ICD-9- 2012100 786.50 Chest pain, (190.17) Prothrombin Time CM codes 786.50 and unspecified (PT) 786.51 to the list of ICD- 9-CM codes that are 786.51 Precordial pain covered by Medicare for the Prothrombin Time (PT) (190.17) NCD. Transmittal # 2344 01/01/12 Per CR 7621 delete ICD- 2012100 425.11 Hypertrophic (190.25) Alpha-fetoprotein 9-CM codes 425.11 and obstructive cardiomyopathy 425.18 from the list of ICD-9-CM codes that are 425.18 Other hypertrophic covered by Medicare for cardiomyopathy the Alpha-fetoprotein (190.25) NCD. Transmittal # 2344 *April 12 Changes – Red Fu Associates, Ltd. April 2012 ii Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit The following section respresents NCD Manual updates for October 2011. 10/01/11 Per CR 7507 delete ICD- 2011400 V19.1 Family history of All NCD Edits 9-CM code V19.1 from other eye disorders the list of ICD-9-CM codes that are denied by Medicare for all 23 Lab NCDs. Transmittal # 2298 10/01/11 Per CR 7507 add ICD-9- 2011400 V19.11 Family history of All NCD Edits CM codes V19.11 and glaucoma V19.19 to the list of ICD- 9-CM codes that are V19.19 Family history of denied by Medicare for other specified eye disorder all 23 Lab NCDs. Transmittal # 2298 10/01/11 Per CR 7507 delete ICD- 2011400 512.8 Other spontaneous 190.14 Human 9-CM code 512.8 from pneumothorax Immunodeficiency Virus the list of ICD-9-CM (HIV) Testing (Diagnosis) codes that are covered by Medicare for the Human Immunodeficiency Virus (HIV) Testing (Diagnosis) (190.14) NCD. Transmittal # 2298 10/01/11 Per CR 7507 add ICD-9- 2011400 512.81 Primary 190.14 Human CM codes 512.81, spontaneous pneumothorax Immunodeficiency Virus 512.82, and 512.83 to (HIV) Testing (Diagnosis) the list of ICD-9-CM 512.82 Secondary codes that are covered spontaneous pneumothorax by Medicare for the Human Immunodeficiency Virus 512.83 Chronic (HIV) Testing pneumothorax (Diagnosis) (190.14) NCD. Transmittal # 2298 *April 12 Changes – Red Fu Associates, Ltd. April 2012 iii Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit 10/01/11 Per CR 7507 delete ICD- 2011400 718.60 Unspecified 190.15 Blood Counts 9-CM codes 718.60 and intrapelvic protrusion of V40.3 from the list of acetabulum, site unspecified ICD-9-CM codes that Do Not Support Medical V40.3 Other behavioral Necessity for the Blood problems Counts (190.15) NCD. Transmittal # 2298 10/01/11 Per CR 7507 add ICD-9- 2011400 726.13 Partial tear of rotator 190.15 Blood Counts CM codes 726.13, cuff V40.31, V40.39, and V54.82 to the list of ICD- V40.31 Wandering in 9-CM codes that Do Not diseases classified Support Medical elsewhere Necessity for the Blood Counts (190.15) NCD. V40.39 Other specified behavioral problem Transmittal # 2298 V54.82 Aftercare following explantation of joint prosthesis *April 12 Changes – Red Fu Associates, Ltd. April 2012 iv Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit 10/01/11 Per CR 7507 delete ICD- 2011400 286.5 Hemorrhagic 190.16 Partial 9-CM codes 286.5, disorder due to intrinsic Thromboplastin Time (PTT) 444.0, and 596.8 from circulating anticoagulants the list of ICD-9-CM codes that are covered 444.0 Embolism and by Medicare for the thrombosis of abdominal Partial Thromboplastin aorta Time (PTT) (190.16) NCD. 596.8 Other specified disorders of bladder Transmittal # 2298 10/01/11 Per CR 7507 add ICD-9- 2011400 286.52 Acquired hemophilia 190.16 Partial CM codes 286.52, Thromboplastin Time (PTT) 286.53, 286.59, 444.01, 286.53 Antiphospholipid 444.09, 573.5, 596.81, antibody with hemorrhagic 596.82, 596.83, and disorder 596.89 to the list of ICD- 9-CM codes that are covered by Medicare for 286.59 Other hemorrhagic the Partial disorder due to intrinsic Thromboplastin Time circulating anticoagulants, (PTT) (190.16) NCD. antibodies, or inhibitors Transmittal # 2298 444.01 Saddle embolus of abdominal aorta 444.09 Other arterial embolism and thrombosis of abdominal aorta 573.5 Hepatopulmonary syndrome 596.81 Infection of cystostomy 596.82 Mechanical complication of cystostomy 596.83 Other complication of cystostomy 596.89 Other specified disorders of bladder *April 12 Changes – Red Fu Associates, Ltd. April 2012 v Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit 10/01/11 Per CR 7507 delete ICD- 2011400 286.5 Hemorrhagic disorder 190.17 Prothrombin Time 9-CM codes 286.5, due to intrinsic circulating (PT) 425.1, 444.0, 596.8, and anticoagulants 997.4 from the list of ICD-9-CM codes that are 425.1 Hypertrophic covered by Medicare for obstructive cardiomyopathy the Prothrombin Time (PT) (190.17) NCD. 444.0 Embolism and thrombosis of abdominal Transmittal # 2298 aorta 596.8 Other specified disorders of bladder 997.4 Digestive system complications, not elsewhere classified *April 12 Changes – Red Fu Associates, Ltd. April 2012 vi Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit 10/01/11 Per CR 7507 add ICD-9- 2011400 286.52 Acquired hemophilia 190.17 Prothrombin Time CM codes 286.52, 286.53 Antiphospholipid (PT) 286.53, 286.59, 414.4, antibody with hemorrhagic 415.13, 425.11, 425.18, disorder 444.01, 444.09, 573.5, 286.59 Other hemorrhagic 596.81, 596.82, 596.83, disorder due to intrinsic 596.89, 997.41, 997.49, circulating anticoagulants, and V12.55 to the list of antibodies, or inhibitors ICD-9-CM codes that are covered by Medicare for the Prothrombin Time 414.4 Coronary (PT) (190.17) NCD. atherosclerosis due to calcified coronary lesion Transmittal # 2298 415.13 Saddle embolus of pulmonary artery 425.11 Hypertrophic obstructive cardiomyopathy 425.18 Other hypertrophic cardiomyopathy 444.01 Saddle embolus of abdominal aorta 444.09 Other arterial embolism and thrombosis of abdominal aorta 573.5 Hepatopulmonary syndrome 596.81 Infection of cystostomy 596.82 Mechanical complication of cystostomy 596.83 Other complication of cystostomy 596.89 Other specified disorders of bladder 997.41 Retained cholelithiasis following cholecystectomy 997.49 Other digestive system complications V12.55 Personal history of pulmonary embolism *April 12 Changes – Red Fu Associates, Ltd. April 2012 vii Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit 10/01/11 Per CR 7507 delete ICD- 2011400 173.0 Other malignant 190.18 Serum Iron Studies 9-CM codes 173.0, neoplasm of skin of lip 173.1, 173.2, 173.3, 173.4, 173.5, 173.6, 173.1 Other malignant 173.7, 173.8, 173.9, and neoplasm of skin of eyelid, 286.5 from the list of including canthus ICD-9-CM codes that are covered by Medicare for the Serum Iron Studies 173.2 Other malignant (190.18) NCD. neoplasm of skin of ear and external auditory canal Transmittal # 2298 173.3 Other malignant neoplasm of skin of other and unspecified parts of face 173.4 Other malignant neoplasm of scalp and skin of neck 173.5 Other malignant neoplasm of skin of trunk, except scrotum 173.6 Other malignant neoplasm of skin of upper limb, including shoulder 173.7 Other malignant neoplasm of skin of lower limb, including hip 173.8 Other malignant neoplasm of other specified sites of skin 173.9 Other malignant neoplasm of skin, site unspecified 286.5 Hemorrhagic disorder due to intrinsic circulating anticoagulants *April 12 Changes – Red Fu Associates, Ltd. April 2012 viii Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. Date Reason Release Change Edit 10/01/11 Per CR 7507 add ICD-9- 2011400 173.00 Unspecified 190.18 Serum Iron Studies CM codes 173.00, malignant neoplasm of skin 173.01, 173.02, 173.09, of lip 173.10, 173.11, 173.12, 173.19, 173.20, 173.21, 173.01 Basal cell carcinoma 173.22, 173.29, 173.30, of skin of lip 173.31, 173.32, 173.39, 173.40, 173.41, 173.42, 173.49, 173.50, 173.51, 173.02 Squamous cell 173.52, 173.59, 173.60, carcinoma of skin of lip 173.61, 173.62, 173.69, 173.70, 173.71, 173.72, 173.09 Other specified 173.79, 173.80, 173.81, malignant neoplasm of skin 173.82, 173.89, 173.90, of lip 173.91, 173.92, 173.99, 282.40, 282.43, 282.44, 173.10 Unspecified 282.45, 282.46, 282.47, malignant neoplasm of 286.52, 286.53, 286.59, eyelid, including canthus and 573.5 to the list of ICD-9-CM codes that are covered by Medicare for 173.11 Basal cell carcinoma the Serum Iron Studies of eyelid, including canthus (190.18) NCD.
Recommended publications
  • WFH Treatment Guidelines 3Ed Chapter 7 Treatment Of

    WFH Treatment Guidelines 3Ed Chapter 7 Treatment Of

    96 TREATMENT OF SPECIFIC 7 HEMORRHAGES Johnny Mahlangu1 | Gerard Dolan2 | Alison Dougall3 | Nicholas J. Goddard4 | Enrique D. Preza Hernández5 | Margaret V. Ragni6 | Bradley Rayner7 | Jerzy Windyga8 | Glenn F. Pierce9 | Alok Srivastava10 1 Department of Molecular Medicine and Haematology, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa 2 Guy’s and St. Thomas’ Hospitals NHS Foundation Trust, London, UK 3 Special Care Dentistry Division of Child and Public Dental Health, School of Dental Science, Trinity College Dublin, Dublin Dental University Hospital, Dublin, Ireland 4 Department of Trauma and Orthopaedics, Royal Free Hospital, London, UK 5 Mexico City, Mexico 6 Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA 7 Cape Town, South Africa 8 Department of Hemostasis Disorders and Internal Medicine, Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland 9 World Federation of Hemophilia, Montreal, QC, Canada 10 Department of Haematology, Christian Medical College, Vellore, India All statements identified as recommendations are • In general, the main treatment for bleeding episodes in consensus based, as denoted by CB. patients with severe hemophilia is prompt clotting factor replacement therapy and rehabilitation. However, different types of bleeds and bleeding at particular anatomical sites 7.1 Introduction may require more specific management with additional
  • Trauma-Associated Pulmonary Laceration in Dogs—A Cross Sectional Study of 364 Dogs

    Trauma-Associated Pulmonary Laceration in Dogs—A Cross Sectional Study of 364 Dogs

    veterinary sciences Article Trauma-Associated Pulmonary Laceration in Dogs—A Cross Sectional Study of 364 Dogs Giovanna Bertolini 1,* , Chiara Briola 1, Luca Angeloni 1, Arianna Costa 1, Paola Rocchi 2 and Marco Caldin 3 1 Diagnostic and Interventional Radiology Division, San Marco Veterinary Clinic and Laboratory, via dell’Industria 3, 35030 Veggiano, Padova, Italy; [email protected] (C.B.); [email protected] (L.A.); [email protected] (A.C.) 2 Intensive Care Unit, San Marco Veterinary Clinic and Laboratory, via dell’Industria 3, 35030 Veggiano, Padova, Italy; [email protected] 3 Clinical Pathology Division, San Marco Veterinary Clinic and Laboratory, via dell’Industria 3, 35030 Veggiano, Padova, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0498561098 Received: 5 March 2020; Accepted: 8 April 2020; Published: 12 April 2020 Abstract: In this study, we describe the computed tomography (CT) features of pulmonary laceration in a study population, which included 364 client-owned dogs that underwent CT examination for thoracic trauma, and compared the characteristics and outcomes of dogs with and without CT evidence of pulmonary laceration. Lung laceration occurred in 46/364 dogs with thoracic trauma (prevalence 12.6%). Dogs with lung laceration were significantly younger than dogs in the control group (median 42 months (interquartile range (IQR) 52.3) and 62 months (IQR 86.1), respectively; p = 0.02). Dogs with lung laceration were significantly heavier than dogs without laceration (median 20.8 kg (IQR 23.3) and median 8.7 kg (IQR 12.4 kg), respectively p < 0.0001). When comparing groups of dogs with thoracic trauma with and without lung laceration, the frequency of high-energy motor vehicle accident trauma was more elevated in dogs with lung laceration than in the control group.
  • Impact of Heterozygous Hemoglobin E on Six Commercial Methods for Hemoglobin A1c Measurement

    Impact of Heterozygous Hemoglobin E on Six Commercial Methods for Hemoglobin A1c Measurement

    Impact of heterozygous hemoglobin E on six commercial methods for hemoglobin A1c measurement Sharon Yong1, Hong Liu1, Cindy Lye Teng Lum2, Qian Liu2, Sin Ye Sim3, Felicia Fu Mun Chay3, Wan Ling Cheng4, Siew Fong Neo4, Suru Chew4, Lizhen Ong4, Tze Ping Loh4, Qinde Liu1, Tang Lin Teo1 and Sunil Kumar Sethi4 1 Chemical Metrology Division, Health Sciences Authority, Singapore, Singapore 2 Department of Pathology, Sengkang General Hospital, Singapore, Singapore 3 Department of Laboratory Medicine, Alexandra Hospital, Singapore, Singapore 4 Department of Laboratory Medicine, National University Hospital, Singapore, Singapore ABSTRACT Background: This study examined the impact of heterozygous HbE on HbA1c measurements by six commonly used commercial methods. The results were compared with those from a modified isotope-dilution mass spectrometry (IDMS) reference laboratory method on a liquid chromatograph coupled with tandem mass spectrometer (LC-MS/MS). Methods: Twenty-three leftover samples of patients with heterozygous HbE (HbA1c range: 5.4–11.6%), and nineteen samples with normal hemoglobin (HbA1c range: 5.0–13.7%) were included. The selected commercial methods included the Tina-quant HbA1c Gen. 3 (Roche Diagnostics, Basel, Switzerland), Cobas B 101 (Roche Diagnostics, Basel, Switzerland), D100 (Bio-Rad Laboratories, Hercules, CA, USA), Variant II Turbo HbA1c 2.0 (Bio-Rad Laboratories, Hercules, CA, USA), DCA Vantage (Siemens Healthcare, Erlangen, Germany) and HbA1c Advanced (Beckman Coulter Inc., Brea, CA, USA). Results: With the exception of Cobas B 101 and the Variant II Turbo 2.0, the 95% confidence intervals of the Passing–Bablok regression lines between the results Submitted 25 September 2020 from the six commercial methods and the IDMS method overlapped.
  • Case Report a Case of a Patient Who Is Diagnosed with Mild Acquired Hemophilia a After Tooth Extraction Died of Acute Subdural Hematoma Due to Head Injury

    Case Report a Case of a Patient Who Is Diagnosed with Mild Acquired Hemophilia a After Tooth Extraction Died of Acute Subdural Hematoma Due to Head Injury

    Hindawi Case Reports in Dentistry Volume 2018, Article ID 7185263, 3 pages https://doi.org/10.1155/2018/7185263 Case Report A Case of a Patient Who Is Diagnosed with Mild Acquired Hemophilia A after Tooth Extraction Died of Acute Subdural Hematoma due to Head Injury Tomohisa Kitamura,1 Tsuyoshi Sato ,1 Eiji Ikami,1 Yosuke Fukushima,1 and Tetsuya Yoda2 1Department of Oral and Maxillofacial Surgery, Saitama Medical University, 38 Moro-hongou, Moroyama-machi, Iruma-gun, Saitama 350-0495, Japan 2Department of Maxillofacial Surgery, Tokyo Medical and Dental University, Tokyo, Japan Correspondence should be addressed to Tsuyoshi Sato; [email protected] Received 13 September 2018; Revised 12 November 2018; Accepted 25 November 2018; Published 9 December 2018 Academic Editor: Yuk-Kwan Chen Copyright © 2018 Tomohisa Kitamura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Acquired hemophilia A (AHA) is a rare disorder which results from the presence of autoantibodies against blood coagulation factor VIII. The initial diagnosis is based on the detection of an isolated prolongation of the activated partial thromboplastin time (aPTT) with negative personal and family history of bleeding disorder. Definitive diagnosis is the identification of reduced FVIII levels with evidence of FVIII neutralizing activity. Case report. We report a case of a 93-year-old female who was diagnosed as AHA after tooth extraction at her home clinic. Prolongation of aPTT and a reduction in factor VIII activity levels were observed with the presence of factor VIII inhibitor.
  • Blood Counts

    Blood Counts

    Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report April 2009 Clinical Diagnostic Laboratory Services Health & Human Services Department Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 CMS Email Point of Contact: [email protected] TDD 410.786.0727 Fu Associates, Ltd. Medicare National Coverage Determinations (NCD) Coding Policy Manual and Change Report This is CMS Logo. NCD Manual Changes Date Reason Release Change Edit The following section represents NCD Manual updates for April 2009. 04/01/09 Per CR 6383 add 2009200 *525.71 Osseointegration *190.15 Blood Counts ICD-9-CM codes failure of dental implant 525.71, 525.72 and 525.73 to the list of ICD-9-CM codes that *525.72 Post- do not support osseointegration Medical necessity for biological failure of the Blood Counts dental implant NCD. *525.73 Post- Transmittal # 1684 osseointegration mechanic failure of dental implant 04/01/09 Per CR 6383 add 2009200 *535.70 Eosinophilic *190.16 Partial ICD-9-CM codes gastritis, without Thromboplastin Time 535.70 and 535.71 to mention of obstruction (PTT) the list of ICD-9-CM codes covered by Medicare for the *535.71 Eosinophilic Partial gastritis, with Thromboplastin Time obstruction NCD. Transmittal # 1684 04/01/09 Per CR 6383 add 2009200 *414.3 Coronary *190.17 Prothrombin ICD-9-CM codes atherosclerosis due to Time 414.3, 535.70 and lipid rich plaque 535.71 to the list of ICD-9-CM codes *535.70 Eosinophilic covered by Medicare gastritis, without mention for the Prothrombin of obstruction Time NCD.
  • Familial Multiple Coagulation Factor Deficiencies

    Familial Multiple Coagulation Factor Deficiencies

    Journal of Clinical Medicine Article Familial Multiple Coagulation Factor Deficiencies (FMCFDs) in a Large Cohort of Patients—A Single-Center Experience in Genetic Diagnosis Barbara Preisler 1,†, Behnaz Pezeshkpoor 1,† , Atanas Banchev 2 , Ronald Fischer 3, Barbara Zieger 4, Ute Scholz 5, Heiko Rühl 1, Bettina Kemkes-Matthes 6, Ursula Schmitt 7, Antje Redlich 8 , Sule Unal 9 , Hans-Jürgen Laws 10, Martin Olivieri 11 , Johannes Oldenburg 1 and Anna Pavlova 1,* 1 Institute of Experimental Hematology and Transfusion Medicine, University Clinic Bonn, 53127 Bonn, Germany; [email protected] (B.P.); [email protected] (B.P.); [email protected] (H.R.); [email protected] (J.O.) 2 Department of Paediatric Haematology and Oncology, University Hospital “Tzaritza Giovanna—ISUL”, 1527 Sofia, Bulgaria; [email protected] 3 Hemophilia Care Center, SRH Kurpfalzkrankenhaus Heidelberg, 69123 Heidelberg, Germany; ronald.fi[email protected] 4 Department of Pediatrics and Adolescent Medicine, University Medical Center–University of Freiburg, 79106 Freiburg, Germany; [email protected] 5 Center of Hemostasis, MVZ Labor Leipzig, 04289 Leipzig, Germany; [email protected] 6 Hemostasis Center, Justus Liebig University Giessen, 35392 Giessen, Germany; [email protected] 7 Center of Hemostasis Berlin, 10789 Berlin-Schöneberg, Germany; [email protected] 8 Pediatric Oncology Department, Otto von Guericke University Children’s Hospital Magdeburg, 39120 Magdeburg, Germany; [email protected] 9 Division of Pediatric Hematology Ankara, Hacettepe University, 06100 Ankara, Turkey; Citation: Preisler, B.; Pezeshkpoor, [email protected] B.; Banchev, A.; Fischer, R.; Zieger, B.; 10 Department of Pediatric Oncology, Hematology and Clinical Immunology, University of Duesseldorf, Scholz, U.; Rühl, H.; Kemkes-Matthes, 40225 Duesseldorf, Germany; [email protected] B.; Schmitt, U.; Redlich, A.; et al.
  • Physiology & Biophysics

    Physiology & Biophysics

    DEPARTMENTAL RESOURCES The Department of Physiology & Biophysics plays a unique role in biological research. It is in effect a conduit through which the powerful techniques and tools of the physical sciences are brought to bear on significant problems of biological importance. The range of problems being addressed in the Department runs the gamut from understanding functionally important atomic scale motions of proteins to characterizing complex behavior on the cellular through organelle level. The tools being used to pursue these cutting edge problems include state of the art instrumentation for magnetic resonance, laser and synchrotron radiation spectroscopies as well as extensive computer modeling. The strength of the Department stems not only from the significant problems that are being aggressively addressed by the departmental faculty, but also from the resources and the collaborative spirit with the department. The Department houses several world class spectroscopy facilities: Biomolecular Laser Research Center (BLRC) The BLRC is composed of three interrelated laser oriented facilities. The laser spectroscopy facility (LSF) contains an extensive array of state-of-the-art laser spectroscopic tools devoted to studying structure, function and dynamics in isolated biomolecules. The laser imaging and microscopy facility (L1MF) focuses on interfacing laser spectroscopy with microscopy to study complex systems at the molecular level. The third facility, devoted to laser based diagnostic tools for clinical applications, is still in the development stage. Pulsed EPR Facility The EPR facility consists of a number of state-of-the-art spectrometers that have been constructed at Einstein. Both theoretical work and experiments are being carried out to define the structure of metal binding sites in metalloproteins and to determine the orientation and distance of substrates to metal centers at active sites of metalloenzymes.
  • Your Baby Has Hemoglobin E Or Hemoglobin O Trait for Parents

    Your Baby Has Hemoglobin E Or Hemoglobin O Trait for Parents

    NEW HAMPSHIRE NEWBORN SCREENING PROGRAM Your Baby Has Hemoglobin E or Hemoglobin O Trait For Parents All infants born in New Hampshire are screened for a panel of conditions at birth. A small amount of blood was collected from your baby’s heel and sent to the laboratory for testing. One of the tests looked at the hemoglobin in your baby’s blood. Your baby’s test found that your baby has either hemoglobin E trait or hemoglobin O trait. The newborn screen- ing test cannot tell the difference between hemoglobin E and hemoglobin O so we do not know which one your baby has. Both hemoglobin E trait and hemoglobin O trait are common and do not cause health problems. Hemoglobin E trait and hemoglobin O trait will never develop to disease. What is hemoglobin? Hemoglobin is the part of the blood that carries oxygen to all parts of the body. There are different types of hemoglobin. The type of hemoglobin we have is determined from genes that we inherit from our parents. Genes are the instructions for how our body develops and functions. We have two copies of each gene; one copy is inherited from our mother in the egg and one copy is inherited from our father in the sperm. What are hemoglobin E trait and hemoglobin O trait? The normal, and most common, type of hemoglobin is called hemoglobin A. Hemoglobin E trait is when a baby inherited one gene for hemoglobin A from one parent and one gene for hemoglobin E from the other parent.
  • Immune-Pathophysiology and -Therapy of Childhood Purpura

    Immune-Pathophysiology and -Therapy of Childhood Purpura

    Egypt J Pediatr Allergy Immunol 2009;7(1):3-13. Review article Immune-pathophysiology and -therapy of childhood purpura Safinaz A Elhabashy Professor of Pediatrics, Ain Shams University, Cairo Childhood purpura - Overview vasculitic disorders present with palpable Purpura (from the Latin, purpura, meaning purpura2. Purpura may be secondary to "purple") is the appearance of red or purple thrombocytopenia, platelet dysfunction, discolorations on the skin that do not blanch on coagulation factor deficiency or vascular defect as applying pressure. They are caused by bleeding shown in table 1. underneath the skin. Purpura measure 0.3-1cm, A thorough history (Table 2) and a careful while petechiae measure less than 3mm and physical examination (Table 3) are critical first ecchymoses greater than 1cm1. The integrity of steps in the evaluation of children with purpura3. the vascular system depends on three interacting When the history and physical examination elements: platelets, plasma coagulation factors suggest the presence of a bleeding disorder, and blood vessels. All three elements are required laboratory screening studies may include a for proper hemostasis, but the pattern of bleeding complete blood count, peripheral blood smear, depends to some extent on the specific defect. In prothrombin time (PT) and activated partial general, platelet disorders manifest petechiae, thromboplastin time (aPTT). With few exceptions, mucosal bleeding (wet purpura) or, rarely, central these studies should identify most hemostatic nervous system bleeding;
  • Implication of Globin Gene Expression, Hemoglobin F and Hemoglobin E Levels on Β-Thalassemia/Hb E Disease Severity

    Implication of Globin Gene Expression, Hemoglobin F and Hemoglobin E Levels on Β-Thalassemia/Hb E Disease Severity

    Available online at www.aNNclinlabsci.org Annals of Clinical & Laboratory Science, vol. 44, no. 4, 2014 437 Implication of Globin Gene Expression, Hemoglobin F and Hemoglobin E Levels on β-Thalassemia/Hb E Disease Severity Suwimol Siriworadechkul1, Sumalee Jindadamrongwech1, SuporN Chuncharunee2, and Saranya Aupparakkitanon1 1Department of Pathology and 2Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand Abstract. One of the factors affecting the degree of severity in β-thalassemia disease is the presence of un- matched α-hemoglobin chains. Thus, the expression levels of globin genes in reticulocytes of β-thalassemia subjects were measured using quantitative RT-PCR, demonstrating that α/β globin mRNA ratio, as well as levels of γ-globin mRNA and Hb F, increased with progressing degree of β globin synthesis defect. The levels of γ-globin mRNA and Hb F could not be directly correlated with severity of β-thalassemia/Hb E disease due to a low statistical power of this analysis. Higher levels of Hb E were present, however, in clini- cally mild patients, as compared to moderately severe β-thalassemia/Hb E subjects. This suggests that in β-thalassemia/Hb E disease, elevation of Hb E level through enhancing correctly spliced βE-globin mRNA offers another approach in ameliorating disease severity. In addition, co-inheritance of α-thalassemia 2 trait in β-thalassemia/Hb E subjects was associated with milder outcome compared with those with the same β-thalassemia genotypes, confirming the notion of the beneficial effect of a more balanced α:β-globin chain ratio. Key words: Globin gene expression, Hemoglobin E, Hemoglobin F, β-thalassemia, modifying factor.
  • Chronic Scrotal Hematocele: a Rare Entity and Diagnostic Dilemma

    Chronic Scrotal Hematocele: a Rare Entity and Diagnostic Dilemma

    Urology & Nephrology Open Access Journal Review Article Open Access Chronic scrotal hematocele: a rare entity and diagnostic dilemma Abstract Volume 4 Issue 5 - 2017 Objective: A comprehensive literature review performed to highlight the clinical and Mohammed Mahdi Babakri surgical aspect of chronic scrotal hematocele. Urology Unit, Aden University, Yemen Material and method: The National Library of Medicine database searched for relevant article using combination of key words: hematocele, scrotal hematocele, chronic hematocele Correspondence: Mohammed Mahdi Babakri, Urology Unit, up to January 2017, irrelevant abstracts excluded and articles reviewed from the clinical, Surgical Department, Faculty of Medicine and Health Sciences, Aden University, Khormaksar, Yemen, P O Box 6038, Tel 00967 radiological and pathological aspects. 777401971, Fax 00967 2 232298, Results and discussion:Chronic scrotal hematocele presented as slowly progressing Email scrotal mass, differentiation from testicular neoplasm is difficult and, in most cases, only possible after surgical removal of the mass. High index of suspicion, especially in slowly Received: March 08, 2017 | Published: April 25, 2017 growing scrotal mass in men older than 50 years, is required to diagnose this pathology and prevent unnecessary orchiectomy. Conclusion:Chronic scrotal hematocele is a rare pathologywith clinical and radiological characteristics similar to testicular tumor, carful patient history taken is crucial to help in proper management. Keywords: chronic scrotal hematocele,scrotal swelling,testicular tumor,hematocele Introduction references from these articles also reviewed and included. The author’s own cases (one published and another one not published yet The differential diagnosis of scrotal swellings is long and includes is included in this review).6 both benign and malignant conditions.
  • Methemoglobinemia and Ascorbate Deficiency in Hemoglobin E Β Thalassemia: Metabolic and Clinical Implications

    Methemoglobinemia and Ascorbate Deficiency in Hemoglobin E Β Thalassemia: Metabolic and Clinical Implications

    From www.bloodjournal.org by guest on April 2, 2015. For personal use only. Plenary paper Methemoglobinemia and ascorbate deficiency in hemoglobin E ␤ thalassemia: metabolic and clinical implications Angela Allen,1,2 Christopher Fisher,1 Anuja Premawardhena,3 Dayananda Bandara,4 Ashok Perera,4 Stephen Allen,2 Timothy St Pierre,5 Nancy Olivieri,6 and David Weatherall1 1MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom; 2College of Medicine, Swansea University, Swansea, United Kingdom; 3University of Kelaniya, Colombo, Sri Lanka; 4National Thalassaemia Centre, District Hospital, Kurunegala, Sri Lanka; 5School of Physics, University of Western Australia, Crawley, Australia; and 6Hemoglobinopathy Research, University Health Network, Toronto, ON During investigations of the phenotypic man hypoxia induction factor pathway is There was, in addition, a highly signifi- diversity of hemoglobin (Hb) E ␤ thalasse- not totally dependent on ascorbate lev- cant correlation between methemoglobin mia, a patient was encountered with per- els. A follow-up study of 45 patients with levels, splenectomy, and factors that sistently high levels of methemoglobin HbE ␤ thalassemia showed that methemo- modify the degree of globin-chain imbal- associated with a left-shift in the oxygen globin levels were significantly increased ance. Because methemoglobin levels are dissociation curve, profound ascorbate and that there was also a significant re- modified by several mechanisms and may deficiency, and clinical features of scurvy; duction in plasma ascorbate levels. Hap- play a role in both adaptation to anemia these abnormalities were corrected by toglobin levels were significantly re- and vascular damage, there is a strong treatment with vitamin C.